InMed Pharmaceuticals (INM) Accounts Payables (2020 - 2026)

InMed Pharmaceuticals has reported Accounts Payables for 7 years, with the latest figure at $1.0 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 28.24% year-over-year to $1.0 million in Q1 2026; TTM through Mar 2026 was $1.0 million, a 28.24% decrease from a year earlier, with the FY2025 full-year figure at $1.2 million, down 25.58% from the prior year.
• Accounts Payables was $1.0 million for Q1 2026 at InMed Pharmaceuticals, down from $1.1 million in the prior quarter.
• The five-year high for Accounts Payables was $2.9 million in Q1 2022, with the low at $1.0 million in Q1 2026.
• Average Accounts Payables over 5 years is $1.6 million, with a median of $1.4 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables soared 47.84% in 2022, then plunged 55.71% in 2023.
• Over 5 years, Accounts Payables stood at $2.0 million in 2022, then tumbled by 34.65% to $1.3 million in 2023, then rose by 6.49% to $1.4 million in 2024, then fell by 21.83% to $1.1 million in 2025, then fell by 5.63% to $1.0 million in 2026.
• The last three Accounts Payables figures came in at $1.0 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.